Sugi Predict

Sugi Predict / Compounds / SCHEMBL310286

SCHEMBL310286

SCHEMBL310286

O=[N+]([O-])c1ccc(F)cc1I

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 3/20 0.64
▸ ATM Q13315 1/20 0.64
▸ HSPB1 P04792 5/20 0.44
▸ PDE7A Q13946 1/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ HIF1A Q16665 2/20 0.42
▸ KCNMA1 Q12791 1/20 0.41
▸ TSHR P16473 4/20 0.41
▸ CYP3A4 P08684 2/20 0.41
▸ PARP1 P09874 1/20 0.41
▸ VCAM1 P19320 1/20 0.40
▸ MAPK1 P28482 2/20 0.39
▸ TTR P02766 1/20 0.39
▸ GPR35 Q9HC97 1/20 0.38
▸ MAPT P10636 2/20 0.38
▸ GAA P10253 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ TP53 P04637 1/20 0.37
▸ HPGD P15428 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30183989 1.00 TDP1 (0.64) TDP1ATMHSPB1PDE7AALDH1A1
SCHEMBL1041139 0.83 ATM (0.59) TDP1ATMHSPB1PDE7AALDH1A1
SCHEMBL31090811 0.83 ATM (0.59) TDP1ATMHSPB1PDE7AALDH1A1
SCHEMBL29745239 0.80 TDP1 (0.72) TDP1ATMHSPB1PDE7AALDH1A1
SCHEMBL216553 0.80 TDP1 (0.72) TDP1ATMHSPB1PDE7AALDH1A1
SCHEMBL1298366 0.78 TSHR (0.43) TDP1ATMALDH1A1TSHRCYP3A4
SCHEMBL29385912 0.78 TDP1 (1.00) TDP1ATMHSPB1PDE7AALDH1A1
SCHEMBL57112 0.78 TDP1 (1.00) TDP1ATMHSPB1PDE7AALDH1A1
SCHEMBL29562216 0.78 TSHR (0.43) TDP1ATMALDH1A1TSHRCYP3A4
SCHEMBL11662435 0.78 TDP1 (0.52) TDP1ATMALDH1A1TSHRCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577267-B2 Pyrimidine compounds for use as MAP4K1 inhibitors GLENMARK SPECIALITY S.A. (CH) 2026-03-17 — — US disclosed
CN-116870016-B Heteroaromatic compound and medical application thereof 希格生科（深圳）有限公司 2024-05-28 — — CN disclosed
CN-117730083-A Pyrimidine compounds as MAP4K1 inhibitors 格兰马克专业公司 2024-03-19 — — CN disclosed
CN-117412981-A Phosphine oxide derivative and preparation method and application thereof 希格生科（深圳）有限公司 2024-01-16 — — CN disclosed
CN-116870016-A Heteroaromatic compound and medical application thereof 希格生科（深圳）有限公司 2023-10-13 — — CN disclosed
US-20230227483-A1 PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS GLENMARK SPECIALITY S.A. (CH) 2023-07-20 — — US disclosed
CN-115785154-A Heteroaromatic ring compounds and medical use thereof 希格生科（深圳）有限公司 2023-03-14 — — CN disclosed
WO-2022253081-A1 PHOSPHINE OXIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 希格生科（深圳）有限公司 2022-12-08 — — WO disclosed
CN-107325002-B Method for synthesizing aryl halide by taking aryl carboxylic acid as raw material 南昌大学 2020-03-27 — — CN disclosed
CN-106687457-B Heteroaryl compounds for kinase inhibition 阿里亚德医药股份有限公司 2020-01-10 — — CN disclosed
US-20100216779-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2010-08-26 — — US disclosed
US-20100216779-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2010-08-26 — — US disclosed
EP-2162454-A1 IMIDAZOPYRIDINE KINASE INHIBITORS GlaxoSmithKline LLC (US) 2010-03-17 — — EP disclosed
WO-2008150799-A1 IMIDAZOPYRIDINE KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-12-11 — — WO disclosed
WO-2008150799-A1 IMIDAZOPYRIDINE KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-12-11 — — WO disclosed
US-20080300242-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2008-12-04 — — US disclosed
US-20080300242-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2008-12-04 — — US disclosed
US-20080300242-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2008-12-04 — — US disclosed
US-6020379-A Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia CELL PATHWAYS, INC. (US) 2000-02-01 — — US disclosed
US-3954852-A Indenylacetic acid compounds MERCK & CO., INC. (US) 1976-05-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300242-A1 Imidazopyridine Kinase Inhibitors ABL1, MAP3K19, MAP3K5 TDP1 1064/4885ATM 724/4885HSPB1 3348/4885
US-12577267-B2 Pyrimidine compounds for use as MAP4K1 inhibitors PTK2B, MAP3K10, MAP3K20 TDP1 714/4885ATM 479/4885HSPB1 1565/4885
US-20100216779-A1 Imidazopyridine Kinase Inhibitors ABL1, MAP3K19, MAP3K5 TDP1 1064/4885ATM 724/4885HSPB1 3348/4885
US-20230227483-A1 PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS MAP4K1, MAP3K4, MAP4K2 TDP1 297/4885ATM 271/4885HSPB1 1073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.